Influenza vaccination in immunocompromised patients: efficacy and safety.
Immunotherapy
; 6(2): 131-9, 2014.
Article
en En
| MEDLINE
| ID: mdl-24491087
ABSTRACT
Yearly administration of the influenza vaccine is the main strategy to prevent influenza in immunocompromised patients. Here, we reviewed the recent literature regarding the clinical significance of the influenza virus infection, as well as the immunogenicity and safety of the influenza vaccine in HIVinfected individuals, solid-organ and stem-cell transplant recipients and patients receiving biological agents. Epidemiological data produced during the 2009 influenza pandemic have confirmed that immunocompromised patients remain at high risk of influenza-associated complications, namely viral and bacterial pneumonia, hospitalization and even death. The immunogenicity of the influenza vaccine is overall reduced in immunocompromised patients, although a significant clinical protection from influenza is expected to be obtained with vaccination. Influenza vaccination is safe in immunocompromised patients. The efficacy of novel strategies to improve the immunogenicity to the vaccine, such as the use of adjuvanted vaccines, boosting doses and intradermal vaccination, needs to be validated in appropriately powered clinical trials.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Orthomyxoviridae
/
Trasplante
/
Vacunas contra la Influenza
/
Infecciones por VIH
/
Huésped Inmunocomprometido
/
Gripe Humana
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Immunotherapy
Año:
2014
Tipo del documento:
Article
País de afiliación:
Suiza